D-045
琥珀酸多西拉敏标准液 溶液
1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H28N2O5
化学文摘社编号:
分子量:
388.46
UNSPSC Code:
41116107
MDL number:
NACRES:
NA.24
EC Number:
200-659-6
InChI key
KBAUFVUYFNWQFM-UHFFFAOYSA-N
InChI
1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
SMILES string
OC(=O)CCC(O)=O.CN(C)CCOC(C)(c1ccccc1)c2ccccn2
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol (as free base)
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
pharmaceutical (small molecule)
format
single component solution
storage temp.
−20°C
Quality Level
Gene Information
human ... HRH1(3269)
General description
Doxylamine is a member of the ethanolamine class of antihistamines and is the most effective over-the-counter (OTC) sedative in the US. This Snap-N-Spike® Reference Solution is applicable to use in LC/MS or GC/MS applications for clinical toxicology or forensic analysis.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Sebastián Videla et al.
Drugs in R&D, 12(4), 217-225 (2012-12-13)
Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European
C L Holder et al.
Journal of analytical toxicology, 11(3), 113-121 (1987-05-01)
Elimination and metabolic profiles of doxylamine and its nonconjugated metabolites were determined after the oral administration of [14C]-doxylamine succinate (13.3 mg/kg and 133 mg/kg doses) to male and female Fischer 344 rats. Total urine and fecal recovery of the administered
A E Rudenko et al.
Likars'ka sprava, (2)(2), 55-59 (2003-05-31)
A positive result has been obtained in treating sleep disorders in patients with chronic vascular affections of the brain with using the drugs donormyl and sonnate-KM [symbol: see text]. Donormyl is recommended for use in sleep disturbances (not very prolonged
B S Somashekar et al.
Magnetic resonance in chemistry : MRC, 42(7), 636-640 (2004-06-08)
A protonation and dynamic structural study of doxylamine succinate, a 1:1 salt of succinic acid with dimethyl-[2-(1-phenyl-1-pyridin-2-yl-ethoxy)ethyl]amine, in solution using one- and two-dimensional 1H and 13C NMR experiments at variable temperature and concentration is presented. The two acidic protons of
Andries Pelser et al.
Biopharmaceutics & drug disposition, 23(6), 239-244 (2002-09-06)
The intranasal route of administration provides a potential useful way of administering a range of systemic drugs. In order to assess the feasibility of this approach for the treatment of nausea and vomiting, doxylamine succinate was studied in rats for
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持